Avalo Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $571 | $236 |
Gross Profit | -343 | 46 | 792 | -11 |
EBITDA | -9,439 | -5,195 | -3,929 | -3,750 |
EBIT | -9,472 | -5,238 | -3,972 | -3,791 |
Net Income | 98,463 | -121,290 | -8,167 | -5,228 |
Net Change In Cash | 0 | 0 | 571 | 236 |
Free Cash Flow | -16,283 | -6,202 | -2,924 | -6,836 |
Cash | 93,426 | 110,181 | 7,416 | 10,180 |
Basic Shares | 7,653 | 859 | 807 | 194 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $1,924 | $18,051 | $5,398 | $6,699 |
Gross Profit | 640 | 14,617 | 3,907 | 6,399 |
EBITDA | -23,286 | -37,422 | -80,586 | -25,212 |
EBIT | -23,444 | -37,588 | -82,243 | -27,055 |
Net Income | -31,544 | -41,658 | -84,349 | -64,384 |
Net Change In Cash | 1,924 | 18,051 | 5,398 | 6,699 |
Cost of Revenue | 15,377 | |||
Free Cash Flow | -30,838 | -26,846 | -71,005 | -40,602 |
Cash | 7,416 | 13,172 | 54,585 | 18,919 |
Basic Shares | 277 | 39 | 36 | 25 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$14.07 |
2024-03-31 | -$141 |
2023-12-31 | -$116.21 |
2023-09-30 | -$0.11 |
